Your browser version may not work well with NCBI's Web applications. More information here...
1: Lupus. 2004;13(5):317-22.Click here to read Links

A therapeutic role for BLyS antagonists.

Stohl W.

Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles 90033, USA. stohl@usc.edu

B lymphocyte stimulator (BLyS) is a vital B cell survival factor. Overexpression of BLyS in mice may lead to systemic lupus erythematosus (SLE)-like disease, and treatment of bona fide SLE mice with BLyS antagonists ameliorates disease progression and enhances survival. BLyS overexpression is common in human SLE, and results from a phase I clinical trial with a BLyS antagonist in human SLE have shown the antagonist to be biologically active and safe. These features collectively point to BLyS as an attractive therapeutic target in human disease.

PMID: 15230285 [PubMed - indexed for MEDLINE]

Related Articles